Published • loading... • Updated
Trump may be mystery patient in odd case of 79yo getting experimental obesity drug
The request, approved for a single 79-year-old man, drew scrutiny because experts said expanded access for common conditions is highly unusual.
- On Tuesday, the Food and Drug Administration and Eli Lilly granted an unidentified 79-year-old man compassionate use access to retatrutide, an experimental obesity drug typically reserved for patients with serious, life-threatening conditions.
- STAT News reported the unusual approval, prompting speculation the patient was President Donald Trump; sources noted the applicant was well-connected and suffered from refractory obesity with obstructive sleep apnea and pulmonary hypertension.
- White House spokesperson Kush Desai denied the application was for the President, attacking reporter Lizzy Lawrence on social media and calling the inquiry 'baseless speculation' while directing questions to the Health and Human Services Department.
- Trump has a documented history of securing rare medical treatments, including Regeneron during his first term and care for cartoonist Scott Adams, while recently expressing public interest in weight-loss medications like GLP-1s.
- Experts told STAT that granting expanded access for common conditions to a single patient is highly unusual, particularly given nearly 4 million Americans in this age cohort face similar health challenges.
Insights by Ground AI
Podcasts & Opinions
18 Articles
18 Articles
Coverage Details
Total News Sources18
Leaning Left11Leaning Right0Center5Last UpdatedBias Distribution69% Left
Bias Distribution
- 69% of the sources lean Left
69% Left
L 69%
C 31%
Factuality
To view factuality data please Upgrade to Premium
